Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
31 Januar 2024 - 11:00PM
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to
focus on unmet needs and apply proven science and new technology to
revolutionize treatment for patients, starting with eye care, today
announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer
and Chairman, will participate in an in-person fireside chat at the
Sixth Annual Guggenheim Healthcare Talks conference in New York
City at 1:00 p.m. ET on Thursday, February 8, 2024.
A live webcast of the fireside chat can be accessed on
the events section of the Tarsus website. Replays will be
available on the Tarsus website within 48 hours and will be
archived for a limited time.
About Tarsus Pharmaceuticals,
Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new
technology to revolutionize treatment for patients, starting with
eye care. Tarsus is advancing its pipeline to address several
diseases with high unmet need across a range of therapeutic
categories, including eye care, dermatology, and infectious disease
prevention. XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA
approved in the United States for the treatment
of Demodex blepharitis. Tarsus is also developing TP-03
as an investigational therapy for the treatment of Meibomian Gland
Disease, which is currently being studied in a Phase 2a clinical
trial. In addition, Tarsus is developing TP-04 for the potential
treatment of Rosacea and TP-05, an oral tablet for the prevention
of Lyme disease. TP-04 and TP-05 are both currently being studied
in Phase 2a clinical trials to evaluate safety, tolerability, and
proof-of activity.
Media Contact:Adrienne KempSr. Director,
Corporate Communications(949) 922-0801AKemp@tarsusrx.com
Investor Contact:David NakasoneHead of Investor
Relations(949) 620-3223DNakasone@tarsusrx.com
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
Von Jan 2024 bis Jan 2025